PROJECTS WORLDWIDE

iPrEX

iPrEX, carried out in Brazil (Fiocruz, UFRJ, and USP), was the first study of PrEP, which involved 2,499 HSH in Latin America, USA, South Africa, and Thailand. The participants, who took Truvada® via oral, had a rate 44% lower of infection by HIV when compared to those that took placebo. Among the patients with adhesion to the treatment, there was a reduction of 92% of the infections by HIV when compared to those volunteers with no detectable level of Truvada® in the visit of the study before the seroconversion.